Oct 22, 2019
The expenditure on drugs and remedies will be increased in 2020 in Germany
Total expenditure on pharmaceuticals and remedies will increase by 4.2% and 0.9% correspondingly in 2020. This is the result of the nationwide framework agreed by the National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband).

The reason for the increase is, as in the past year, in particular, the use of innovative medicines, benefiting primarily oncological patients. Therefore, this is an essential prerequisite that seriously ill patients can profit from new treatment options.

The framework specifications form the basis for the regional negotiations on the volume of expenditures that the Associations of Statutory Health Insurance Physicians (KVen) carry out with the local health insurance companies. In addition to the adjustment, factors agreed at the federal level, such as price development and the use of innovative medicines, other factors such as age and number of insured persons are taken into account in the negotiations at the regional level.

KBV and GKV-Spitzenverband are also expecting higher expenditure on remedies in the coming year. The agreed increase is 0.9% compared to the current year. Among other things, this assessment included the transfer of services from the inpatient to outpatient sectors. In the case of medicines, additional factors are also regionally negotiated between the health insurance funds and the health insurance companies. These include the development of remedies prices, the number of insured, and their age structure.

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Close
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)